<DOC>
	<DOC>NCT01042236</DOC>
	<brief_summary>The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence</brief_summary>
	<brief_title>Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Female, 18 65 years SUI symptoms for longer than 3 months Subjects must be nonpregnant and not breastfeeding Disease or medical condition affecting the bladder or urinary tract (other tan stress urinary incontinence) Subjects taking medication with effects on the bladder or urinary tract Subejcts with medical conditions which could be adversely affected by administration of fesoterodine gastrointestinal tract disease, glaucoma, hepatic impairment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Phase 2 stress urinary incontinence Fesoterodine</keyword>
</DOC>